13F Pro13F Pro

SEC Form 4 reporting owner

Nelsen Robert

Nelsen Robert has filed 10 Form 4 transactions reported between June 4, 2026 and October 19, 2026, as Director of CITY THERAPEUTICS, INC., Director of Prime Medicine, Inc. and Director of Sana Biotechnology, Inc..

Name as filed: NELSEN ROBERT

Follow Nelsen Robert and get an alert on every new Form 4

Nelsen Robert holds 13.7M shares of CTY, worth $284.7M.

As of their Oct 15, 2026 Form 4 (filed Oct 19, 2026) · the filing on SEC EDGAR · valued at the Oct 26, 2026 close of $20.79

Open-market buys, 24 mo
$3.1M
1 lines
Open-market sales, 24 mo
None
reported
Companies
3
with Form 4 filings
Latest transaction
Oct 19, 2026
transaction date

Roles and reported holdings

  • CTYCITY THERAPEUTICS, INC.
    Oct 15, 2026 – Oct 19, 2026

    Director

    By ARCH Venture Fund XII, L.P.13,692,507 sh

    Also reports 22,649 Stock Option (Right to Buy), not counted as shares.

    As of Oct 15, 2026 · Form 4

    24 months: $3.1M bought

  • PRMEPrime Medicine, Inc.
    Jun 5, 2026

    Director

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • SANASana Biotechnology, Inc.
    Jun 4, 2026

    Director

    No common-stock holding reported on a purchase, sale, gift or withholding line.

How their buys did since

1 open-market purchase against today’s price: +15.5% on average.

DatePaidReturn
Oct 19, 2026CTY$18.00+15.5%now $20.79

Each purchase at the price on its Form 4, against the latest trade or close, adjusted for stock splits. Past returns say nothing about future ones.

Transaction history

All 10 reported transactions, newest first. Every row links to the Form 4 on SEC EDGAR.

DateCompanyTypeSharesValueFiling
Oct 19, 2026CTYDirectorConversion of derivativeCode C · indirect1,845,585—Form 4
Oct 19, 2026CTYDirectorConversion of derivativeCode C · indirect4,991,633—Form 4
Oct 19, 2026CTYDirectorConversion of derivativeCode C · indirect3,000,000—Form 4
Oct 19, 2026CTYDirectorOpen-market purchaseCode P · indirectAlso reported by ARCH Venture Partners XII, LLC170,000$3.1M@ $18.00Form 4
Oct 19, 2026CTYDirectorConversion of derivativeCode C · indirect2,027,006—Form 4
Oct 19, 2026CTYDirectorConversion of derivativeCode C · indirect5,482,309—Form 4
Oct 19, 2026CTYDirectorConversion of derivativeCode C · indirect3,294,900—Form 4
Oct 15, 2026CTYDirectorGrant or awardCode A · direct22,649—Form 4
Jun 5, 2026PRMEDirectorGrant or awardCode A · direct75,000—Form 4
Jun 4, 2026SANADirectorGrant or awardCode A · direct90,000—Form 4

How this page is built

Every row comes from a Form 4 filed with the SEC, which officers, directors and holders of more than 10% of a company’s stock must file within two business days of a trade. Transactions are grouped by the reporting owner’s name as filed (spacing, capitals and punctuation ignored); two different people filing under an identical name would appear together, and one person filing under two spellings appears on two pages.

Open-market totals count code P purchases and code S sales over the last 24 months. The same trade reported on more than one filing is counted once; when another owner (for example a fund and its general partner) reports the identical trade, they are listed beside it. Holdings are the shares each ownership line is left at by the person’s latest Form 4, 4/A or 5: held directly, and through each trust or entity named on the filing. A second class of common stock that converts into the listed one counts as shares; options and restricted stock units are listed but not counted. Value uses the latest trade or close, and the share of the company uses the latest shares-outstanding count the company reported. Where a filing has not yet been read line by line, the figure comes from the latest direct and indirect lines that traded and is shown as “at least”.

This page describes what was filed with the SEC; it is not investment advice or a recommendation to buy or sell any security.